Dermapharm Holding SE (ETR:DMP)
Germany · Delayed Price · Currency is EUR 48.75
-0.35 (-0.71%)
May 29, 2026, 5:35 PM CET
Dermapharm Holding SE Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,181 | 1,177 | 1,195 | 1,150 | 1,040 | 959.6 |
Other Revenue | 0.92 | 0.92 | 0.75 | 0.42 | 0.25 | 0.49 |
| 1,182 | 1,178 | 1,195 | 1,151 | 1,041 | 960.09 | |
Revenue Growth (YoY) | -1.42% | -1.43% | 3.89% | 10.59% | 8.38% | 18.78% |
Cost of Revenue | 407.97 | 412.65 | 445.6 | 446.6 | 391.85 | 349.87 |
Gross Profit | 774.27 | 765.74 | 749.85 | 704.14 | 648.7 | 610.22 |
Selling, General & Admin | 302.64 | 299.27 | 287.43 | 271.01 | 190.56 | 168.95 |
Other Operating Expenses | 147.49 | 149.03 | 158.18 | 151.21 | 117.72 | 99.68 |
Operating Expenses | 531.36 | 529.12 | 527.78 | 510.99 | 365.98 | 314.31 |
Operating Income | 242.91 | 236.62 | 222.07 | 193.16 | 282.72 | 295.91 |
Interest Expense | -46.48 | -48.67 | -58.41 | -54.97 | -12.34 | -8.84 |
Interest & Investment Income | 4.64 | 5.61 | 13.99 | 2.49 | 0.33 | 4.02 |
Earnings From Equity Investments | 4.08 | 4.34 | 1.52 | -7.16 | -13.54 | 0.32 |
Currency Exchange Gain (Loss) | -4.81 | -4.81 | 1.4 | -1.95 | 0.37 | 2.28 |
Other Non Operating Income (Expenses) | 6.34 | 1.75 | -0.96 | -16.63 | -1.12 | -0.83 |
EBT Excluding Unusual Items | 206.68 | 194.84 | 179.61 | 114.93 | 256.43 | 292.86 |
Merger & Restructuring Charges | - | - | - | - | - | -0.6 |
Impairment of Goodwill | -10.82 | -10.82 | -2.12 | - | -36.45 | -5.43 |
Gain (Loss) on Sale of Investments | - | - | -0 | -1.98 | - | 9.06 |
Gain (Loss) on Sale of Assets | 0.28 | 0.28 | 0.63 | 2.96 | 3.13 | 1.38 |
Asset Writedown | -0.92 | -0.92 | -6.21 | -15.82 | -7.03 | -4.48 |
Other Unusual Items | - | - | - | 5.78 | - | - |
Pretax Income | 195.35 | 183.51 | 172.01 | 106 | 216.3 | 292.98 |
Income Tax Expense | 52.07 | 52.16 | 60.27 | 45.46 | 83.68 | 84.07 |
Earnings From Continuing Operations | 143.28 | 131.35 | 111.74 | 60.53 | 132.62 | 208.9 |
Minority Interest in Earnings | 0.93 | 1.06 | 2.05 | 1.83 | 1.62 | 0.68 |
Net Income | 144.21 | 132.41 | 113.79 | 62.37 | 134.24 | 209.58 |
Net Income to Common | 144.21 | 132.41 | 113.79 | 62.37 | 134.24 | 209.58 |
Net Income Growth | 39.23% | 16.37% | 82.45% | -53.54% | -35.95% | 144.19% |
Shares Outstanding (Basic) | 54 | 54 | 54 | 54 | 54 | 54 |
Shares Outstanding (Diluted) | 54 | 54 | 54 | 54 | 54 | 54 |
Shares Change (YoY) | -0.04% | - | - | - | - | - |
EPS (Basic) | 2.68 | 2.46 | 2.11 | 1.16 | 2.49 | 3.89 |
EPS (Diluted) | 2.68 | 2.46 | 2.11 | 1.16 | 2.49 | 3.89 |
EPS Growth | 39.30% | 16.37% | 82.45% | -53.54% | -35.91% | 144.65% |
Free Cash Flow | 240.85 | 187.03 | 163.14 | 177.88 | 249.52 | 189.17 |
Free Cash Flow Per Share | 4.47 | 3.47 | 3.03 | 3.30 | 4.63 | 3.51 |
Dividend Per Share | 0.880 | 0.880 | 0.900 | 0.880 | 1.050 | 2.170 |
Dividend Growth | -2.22% | -2.22% | 2.27% | -16.19% | -51.61% | 146.59% |
Gross Margin | 65.49% | 64.98% | 62.72% | 61.19% | 62.34% | 63.56% |
Operating Margin | 20.55% | 20.08% | 18.58% | 16.79% | 27.17% | 30.82% |
Profit Margin | 12.20% | 11.24% | 9.52% | 5.42% | 12.90% | 21.83% |
Free Cash Flow Margin | 20.37% | 15.87% | 13.65% | 15.46% | 23.98% | 19.70% |
EBITDA | 271.38 | 264.74 | 250.77 | 220.31 | 302.36 | 312.36 |
EBITDA Margin | 22.96% | 22.47% | 20.98% | 19.14% | 29.06% | 32.53% |
D&A For EBITDA | 28.48 | 28.12 | 28.7 | 27.15 | 19.64 | 16.45 |
EBIT | 242.91 | 236.62 | 222.07 | 193.16 | 282.72 | 295.91 |
EBIT Margin | 20.55% | 20.08% | 18.58% | 16.79% | 27.17% | 30.82% |
Effective Tax Rate | 26.66% | 28.42% | 35.04% | 42.89% | 38.69% | 28.70% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.